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Abstract 
 
Inflammation is implicated in the etiology of Major Depressive Disorder (MDD). Human 
neuroimaging techniques are increasingly used to characterize the neural circuitry mediating 
actions of inflammation on mood, motivation and cognition and its relationship to MDD. In 
this issue, Byrne and colleagues report the first systematic review of these studies. The 
systematic review provides a much-needed synthesis of current research findings and 
highlights the role of cortical and subcortical brain structure and function. In this 
accompanying commentary, we highlight further points of particular relevance to future 
studies, including the potential advantages of functional phenotype models rather than the 
emphasis on mutually exclusive diagnostic categories in describing MDD and other 
psychiatric disorders. Novel imaging techniques will further enhance possibilities to clarify 
the link between inflammation and depression. New research challenges are described 
regarding the relationships between behavioural phenotype, brain structure and function, and 
peripheral inflammation.  
  
Major Depressive Disorder (MDD) is one of the leading causes of disability worldwide and 
significantly worsens prognosis and quality of life for people with comorbid physical 
disorders. Yet despite this major global burden, advances in understanding MDD 
pathogenesis have been slow, and translational breakthroughs disappointingly rare. Over the 
past two decades a surge of research has focused on understanding the role of inflammation 
in major mental illnesses. In MDD, characteristic alterations in serum cytokines, chemokines 
and acute phase reactant protein concentrations have been confirmed in at least 4 recent 
meta-analyses (1-4). Furthermore, longitudinal studies suggest that inflammatory changes 
predate and likely contribute to the development of depressive symptoms (5); findings that 
accord with the observation that 1 in 4 patients treated with Interferon-alpha (for hepatitis-C) 
develop MDD. These studies challenge the long held view of the brain as an ‘immune 
privileged site’. By characterizing the bi-directional interactions between physiological stress 
responses, immune/inflammatory pathways and the brain, they are also beginning to offer a 
coherent neurobiological framework for understanding this multi-componential disorder (6, 
7). This framework additionally offers the prospect of identifying circulating inflammatory 
biomarkers for treatment response, and novel anti-inflammatory agents as adjunctive 
therapies for treatment resistance (8, 9). 
While preclinical studies have helped clarify actions of systemic inflammation on regional 
brain structure and function, the use of advanced brain imaging techniques to explore similar 
relationships in clinical studies remains in a fledgling state.  
In the current issue of Psychosomatic Medicine, Byrne and colleagues report the first 
systematic review of studies using brain imaging to characterize the neural mechanisms 
linking inflammation and depressive symptoms (10). They reviewed 26 studies that report 
effects of both experimentally induced inflammation and inflammation in the context of 
MDD and identify a cluster of subcortical (basal ganglia, ventral striatum, hippocampus, 
hypothalamus and amygdala) and cortical (insula, anterior cingulate, orbitofrontal, 
ventromedial, and dorsolateral prefrontal cortices) structures that appear central to effects of 
inflammation on mood and depressive symptomatology. This review provides a much-needed 
synthesis of current research findings, highlights caveats of the existing literature and points 
towards potential pathways for future research. In this editorial, we highlight issues that will 
need to be addressed in future studies exploring relationships between behavioural phenotype, 
brain and peripheral inflammation, and examine how refining these measurements will be 
crucial to further progress. 
 
Measuring the right phenotype:  
While most studies find a relationship between inflammation and MDD, it is important to 
note that a significant proportion of people with MDD do not show raised inflammatory 
markers. Furthermore, immune/inflammatory disruption is also found in a number of other 
psychiatric conditions, including schizophrenia and PTSD (11, 12). Inflammation is therefore 
neither necessary nor specific to MDD. Complicating this further, we know that depressive 
symptoms are not limited to MDD, but instead are common in patients diagnosed with a 
range of other illnesses including anxiety disorders and psychosis. This highlights the highly 
heterogeneous nature of current psychiatric diagnostic categories (13) which frequently share 
overlapping symptomatology, genetic and biological susceptibility (14) and likely mitigates 
success of attempts to map diagnoses to specific alterations in brain structure/function. This 
problem is widely acknowledged across psychiatric research and has led to the recognition 
that a categorical (diagnostic criteria based) approach may be impeding biologically relevant 
translational research (15). In keeping with this, there is a move to replace existing 
categorical models of mental illnesses, with trans-diagnostic dimensional models that 
incorporate genes, biology and cognitive neuroscience (16). There is also a move towards 
implementing computational models of psychiatric symptomatology that may better map 
complex cognitive and behavioural constructs at the neuronal level (17). Therefore, rather 
than exploring associations within specific illness categories, future research may need to 
look at associations between inflammation and research domains or computational models of 
complex cognitive/ behavioural functions. 
Measuring the brain: 
Neuroimaging is a fast evolving field. While traditional neuroimaging approaches have 
examined how measured variables (cognitive function/ inflammatory markers) are 
correlated with patterns of activation, volume or metabolism on a region-by-region 
basis, more recent studies have focused on "how" these processes are implemented 
and distributed across brain regions using advanced computational modelling. The 
latter approaches are enabling us to better understand how networks of regions 
interact together to support complex behaviors. 
By regressing variables derived from competing computational models of a specific cognitive 
function, model-based approaches to fMRI provide insight into ‘how’ rather than simply 
‘where’ a particular cognitive process is implemented within the brain. This approach also 
has the potential to provide a more fine-grained understanding of brain responses to 
inflammation. For example, in their review, Byrne et al. identify the ventral striatum and 
insula as key brain regions sensitive to systemic inflammation. Using a reinforcement-
learning model, Harrison et al. deconstruct the concept of 'motivational reorientation', a core 
feature of inflammation induced sickness-behavior, to show that experimentally induced 
inflammation significantly enhances sensitivity to punishments versus rewards 
(18). Furthermore, they showed that prediction error (PE) signals (difference between 
expected and obtained reward/punishment) believed to guide learning were significantly 
modulated by inflammation, with inflammation prompting a significant reduction in ventral 
striatal encoding of reward PE and a converse enhancement of insula encoding of punishment 
PE. Model-based studies such as this will be essential to future attempts to understand how 
inflammation alters specific neural computational mechanisms that lead to observed changes 
in behavior. 
A second approach gaining increasing importance is the use of resting state fMRI to explore 
how dynamically interacting core intrinsic connectivity networks (ICN), are altered by 
inflammatory stimuli. For example, Felger et al. recently showed an inverse association 
between circulating C-reactive protein (CRP) levels and striatal functional connectivity in 
MDD (19). Other key substrates identified by Byrne et al. include the anterior insula and 
anterior cingulate cortices. These regions are noteworthy as they both form key nodes of the 
salience network (SN) implicated in allocating attentional resources to behaviorally relevant 
external and internal stimuli (20-22). Furthermore, internal (interoceptive) signals from the 
body are postulated to have a primary 'viscero-cortical' representation within the SN. 
Inflammatory mediators, are known to activate vagal afferents and the sensory 
circumventricular organs as well as the brainstem ‘viscerosensory hub’ evoking visceral 
reflexes and subjective experiences of fatigue, malaise, and anorexia (21, 23). Further 
upstream, involvement of the SN may also be associated with aberrant salience mapping (24). 
The centrality of the insula to autonomic, interoceptive, and viscero-cortical representation, 
together with its role in ‘switching’ between brain states, make it an ideal candidate for 
investigating how interoceptive inflammatory signals modulate complex neurocognitive 
function.  
Resting state fMRI has also been used to explore effects of inflammation on global network 
function using graph theoretical metrics derived from complex network analysis (CNA). 
Using CNA of resting state BOLD cross-correlations Dipasquale et al. have recently shown 
that peripherally administered IFN-α rapidly reduces global network connectivity and 
network efficiency indicating a global reduction in information transfer among nodes forming 
the whole brain network (25). Similar data-driven approaches could include investigating 
how inflammation affects the regional homogeneity (ReHo) of BOLD signals, a measure 
shown to be disrupted in a regionally specific manner in MDD (26). In this regard, Byrne et 
al. found evidence to support effects of inflammation on glutamatergic activity (10). 
Measures such as the amplitude of low frequency fluctuations (alFF) may be a useful index to 
further quantify how these inflammation-induced changes in glutamatergic function relate to 
observed alterations in BOLD fluctuations at rest (27). Finally, newer MRI based sequences 
like quantitative magnetization transfer (qMT), neurite orientation dispersion and density 
imaging (NODDI) and free water imaging also appear to be promising approaches for 
characterizing effects of inflammation on brain pathophysiology (28-30). Future studies are 
likely to see increasing use of these complimentary imaging technologies to understand how 
inflammation-induced changes in brain microstructure relate to associated changes in 
function. 
Measuring inflammatory markers: 
Three points appear crucial when measuring inflammatory markers. Firstly, it is essential to 
dissect effects of 'non-sterile' inflammation (induced by infection/experimental 
cytokines/vaccines/endotoxins) from inflammation secondary to 'sterile' stressors e.g. 
psychological stress (31) and furthermore recognize that not all ‘non-sterile’ challenges 
recruit the same signal transduction pathways (32). Although there is increasing evidence for 
"inflammasome" activation and aggregation in response to both sterile and non-sterile 
inflammation, these effects still need to be qualified and quantified (33, 34). Similarly, while 
experimental induction of inflammation may help quantify effects of inflammation in the 
absence of confounding factors, in real life this is rarely the case. For example, previous 
studies have illustrated how inflammatory markers may mediate the relationship between 
socioeconomic status and grey/ white matter structure (35-37). However, it remains unclear 
whether inflammatory pathways linking real-life sustained stressful conditions to the brain 
differ from those associated with experimentally induced inflammation. 
Secondly, it remains unclear to what extent  circulating inflammatory markers reflect central 
levels. While most of the studies reviewed by Byrne and colleagues examined associations 
between circulating inflammatory markers and brain structure/ function, few measured 
central inflammatory markers. In this regard it is interesting to note that Haroon et al., 
recently found a high correlation between plasma and cerebrospinal fluid (CSF) CRP, yet 
only plasma measures correlated with basal ganglia glutamate (38). Other studies have found 
no relationship between circulating and CSF inflammatory markers (39, 40).  Measuring 
CSF/central inflammation is further complicated by the presence of both soluble and cell 
bound cytokines fractions in the brain. For example, microglial activity produces 
predominantly bound tumor necrosis factor (TNF) that is difficult to measure (39). Moreover, 
there has not been a consistent relationship between CSF inflammatory markers and MDD 
(40-42). Some studies have used 18nDa translocator protein (TSPO) Positron Emission 
Tomography (PET) which is expressed on activated microglia to quantify central 
inflammation. In an interesting recent study, Sandiego et al. showed that endotoxin challenge 
in healthy adults results in rapid and widespread microglial activation throughout the brain 
(43). However, findings using TSPO binding in MDD have been mixed (10). Furthermore, 
TSPO PET studies are not without their own difficulties. TSPO PET is expensive, existing 
TSPO ligands like [11C]PK11195 have poor signal to noise ratio and newer tracers like 
[11C]PBR28 show marked between subject variations in binding affinity (44). Additionally, 
not all microglia express TSPO, and TSPO PET cannot differentiate an increase in microglial 
number from an increase in TSPO expression within each microglia (44).  
 A third issue is identifying what markers of inflammation should we be measuring. 
Most research to date has focused on investigating relationships between pro-inflammatory 
cytokines and psychiatric illnesses. Similarly, most of the studies cited by Byrne et al. only 
measured cytokines identified by the meta-analyses linking inflammation to depression (4). 
Here, the underlying assumption is that excess pro-inflammatory cytokines are harmful to the 
brain. However, it is clear that some pro-inflammatory cytokines such as TNF are required 
for healthy CNS function (45). While a simple division between pro-and anti-inflammatory 
cytokines may be artificial, a balance between different inflammatory markers clearly exists 
within the body. Furthermore, chemokines and colony-stimulating factors have also been 
linked to cognitive dysfunction and the pathophysiology of psychiatric symptom clusters 
(46). Given the complex interplay between these factors sophisticated modeling using 
techniques such as principal component analysis, hierarchical or other advanced clustering 
techniques are likely to be required to fully capture how changes in networks of interacting 
inflammatory markers act on the brain to induce associated changes in behavior and 
cognition (47).  
To conclude, raised inflammatory markers have been associated with a number of psychiatric 
conditions including depression and may indeed play an etiological role in these disorders. 
Inflammation may perhaps be better conceptualized as a generalized physiological (or 
pathological) response to a stressor (sterile or non-sterile) that triggers a cascade of events 
that affect core information processing systems in the brain, leading ultimately to a discrete 
behavioural phenotype (e.g. anhedonia / motivational reorientation) that spans diagnostic 
categories.  Although the key mechanisms linking inflammatory factors to the human brain 
are gradually being established, future work will need to focus on refining peripheral immune 
measures. These research findings, together with the application of advanced brain-imaging 
techniques, should help us to move closer to the goal of understanding more precisely the 
relationship between peripheral inflammation, regional brain structure / function and 
associated changes in discrete clinical and cognitive phenotypes. 
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